| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/CLPT.1982.54 |
| P698 | PubMed publication ID | 7060323 |
| P2093 | author name string | R G McAllister | |
| E B Kirsten | |||
| P433 | issue | 4 | |
| P921 | main subject | pharmacology | Q128406 |
| P304 | page(s) | 418-426 | |
| P577 | publication date | 1982-04-01 | |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses | |
| P478 | volume | 31 |
| Q68535413 | 24-hour antiarrhythmic effect of conventional and slow-release verapamil in chronic atrial fibrillation |
| Q36705746 | Chiral aspects of drug action at ion channels: A commentary on the stereoselectivity of drug actions at voltage-gated ion channels with particular reference to verapamil actions at the Ca2+ channel |
| Q40167931 | Clinical Pharmacokinetics of Verapamil |
| Q47913024 | Clinical pharmacokinetics of vasodilators. Part I. |
| Q39754378 | Clinical pharmacokinetics of verapamil, nifedipine and diltiazem |
| Q44701783 | Comparative efficacies and durations of action of phenoxybenzamine, verapamil/nitroglycerin solution, and papaverine as topical antispasmodics for radial artery coronary bypass grafting |
| Q37624739 | Comparison of study designs used to detect and characterize pharmacogenomic interactions in nonexperimental studies: a simulation study |
| Q34708717 | Drug Prescribing in Renal Failure: Dosing Guidelines for Adults |
| Q71797500 | Effect of verapamil on retrograde atrioventricular nodal conduction in the human heart |
| Q34257205 | First-pass elimination. Basic concepts and clinical consequences |
| Q35027993 | Human vascular to cardiac tissue selectivity of L- and T-type calcium channel antagonists |
| Q46706108 | Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles |
| Q52334679 | Improved Predictions of Drug-Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A. |
| Q40791116 | Individual variation in first-pass metabolism |
| Q42246055 | Influence of ABCB1 gene polymorphisms on the pharmacokinetics of verapamil among healthy Chinese Han ethnic subjects |
| Q46775569 | Influence of famotidine on verapamil pharmacokinetics in rats |
| Q67549648 | Low-dose verapamil in middle-aged and elderly patients with angina pectoris: no evidence of increased susceptibility to the cardiac effects |
| Q34146073 | Metabolite parameters as an appropriate alternative approach for assessment of bioequivalence of two verapamil formulations |
| Q70236907 | Neuromuscular blocking action of verapamil in cats |
| Q52262360 | New mathematical implementation of generalized pharmacodynamic models: method and clinical evaluation. |
| Q72594145 | Once-daily verapamil |
| Q69426469 | Pharmacokinetic characterization of the antiarrhythmic drug diprafenone in man |
| Q34417142 | Pharmacokinetics and pharmacodynamics of two formulations of verapamil |
| Q42005077 | Pharmacokinetics and pharmacodynamics of verapamil following sublingual and oral administration to healthy volunteers |
| Q69397319 | Pharmacokinetics and systemic availability of the antihypertensive agent indoramin and its metabolite 6-hydroxyindoramin in healthy subjects |
| Q42532060 | Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration |
| Q60777249 | Pharmacokinetics of sustained-release verapamil after a single administration and at steady state |
| Q69720626 | Pharmacokinetics of verapamil in patients with hypertension |
| Q49323041 | Pharmacokinetics of verapamil in patients with renal failure |
| Q52679386 | Plasma levels and myocardial content of verapamil, norverapamil and two N-dealkyl-metabolites in man. |
| Q36970461 | Poisoning due to calcium antagonists. Experience with verapamil, diltiazem and nifedipine |
| Q43554159 | Race but not age affects erythromycin breath test results in older hypertensive men. |
| Q72032420 | Simultaneous analysis of verapamil and norverapamil enantiomers in human plasma by high-performance liquid chromatography |
| Q73483060 | Simultaneous determination of verapamil and norverapamil in biological samples by high-performance liquid chromatography using ultraviolet detection |
| Q80084101 | Spline functions in convolutional modeling of verapamil bioavailability and bioequivalence. II: study in healthy volunteers |
| Q42126042 | Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique |
| Q70328377 | Sustained release verapamil, a once daily preparation: objective evaluation using exercise testing, ambulatory monitoring and blood levels in patients with stable angina |
| Q42231825 | The effect of oral verapamil therapy on antipyrine clearance |
| Q39459895 | The haemodynamic effects of nifedipine, verapamil and diltiazem in patients with coronary artery disease. A review |
| Q39318415 | The peripheral vascular effects of diltiazem--dose-response characteristics |
| Q43791599 | Transient kinetic and dynamic interactions between verapamil and dofetilide, a class III antiarrhythmic |
| Q38204833 | Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships |
| Q80266410 | Validation of the hepatic blood flow rate model for verapamil first-pass metabolism |
| Q69785638 | Verapamil and norverapamil in plasma and breast milk during breast feeding |
| Q41816741 | Verapamil disposition and cardiovascular effects in elderly patients after single intravenous and oral doses |
| Q34622354 | Verapamil disposition--effects of sulphinpyrazone and cimetidine |
| Q43240156 | Verapamil pharmacokinetics and apparent hepatic and renal blood flow |
| Q85218196 | Verapamil sustained release: New formulation and convolution |
| Q38679740 | Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension |
Search more.